-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2024-516137-13-00
5
2014-12-18
Metastatic Prostate Cancer
-
2024-516801-22-00
5
2012-04-26
Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-N
-
2024-518954-18-01
6
2024-12-05
Post-surgical scar pain
-
2023-504179-26-00
6
2024-07-19
Acute Venous Thromboembolism
-
2023-506696-10-00
5
2024-06-18
Non-Small Cell Lung Cancer
-
2023-503614-80-00
5
2023-12-14
Pulmonary Arterial Hypertension
-
2023-504487-41-00
5
2023-11-28
COVID-19
-
2022-501020-19-01
5
2023-07-31
COVID-19
-
2023-508735-31-00
5
2023-05-05
Pulmonary Arterial Hypertension (PAH)
-
2023-506931-13-00
5
2023-01-30
Overweight and obesity and type 2 diabetes
-
2023-509569-19-00
10
2022-08-10
venous thromboembolism (VTE)
-
2022-501132-42-00
6
2022-08-02
Monkeypox virus disease
-
2023-508734-34-00
10
2022-06-30
Pulmonary Arterial Hypertension (PAH)
-
2022-500385-99-00
5
2021-06-03
SARS-CoV II infection (Coronavirus disease)
-
2023-505167-36-00
5
2019-08-05
Patients who present late on during their acquisition of the HIV-1
(Hu
-
2024-511972-33-00
5
2019-08-05
Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
-
2023-508832-68-00
9
2019-03-28
Recurrent or stage IVB cervical cancer
-
2022-500797-34-00
4
2018-12-17
Treatment of participants with positive cancer for HRRm or HRD.
-
2023-507294-18-00
5
2016-09-16
Metastatic renal cell carcinoma
-
2023-509137-39-00
5
2015-11-06
Stage IB (T ≥ 4 cm), II and IIIA NSCLC
-
2024-514808-13-00
5
2015-03-06
Localised prostate cancer at high risk of recurrence
-
2022-501353-37-00
5
Reversal of anticoagulation effect in patients on a FXa inhibitor (api
-
2023-506967-33-00
4
Stroke